FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306255564> ?p ?o ?g. }

• W4306255564 abstract "Abstract Background Circulating Endothelin-1 (ET-1) is associated with heart failure (HF) severity and has also been widely implicated in the pathophysiology of renal disease. However, its prognostic importance and relationship with kidney function in patients with HFrEF receiving contemporary treatment is uncertain. Purpose To investigate the association of ET-1 with heart failure outcomes, as well as change in kidney function; and the efficacy of dapagliflozin according to baseline serum ET-1 in the Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF). Methods Serum ET-1 was measured at randomization and at 12 months and analysed using a Microfluidics immunoassay. We investigated the incidence of the primary outcome (cardiovascular death or worsening HF), and analysed change in kidney function according to tertile of baseline ET-1 concentration. Additionally, we assessed whether baseline ET-1 modified the treatment effect of dapagliflozin. Results Of 4744 randomized participants, 3048 (64.2%) had a baseline ET-1 measurement: tertile 1 (≤3.28 pg/mL, n=1016), tertile 2 (&gt;3.28 to 4.41 pg/mL, n=1022), and tertile 3 (&gt;4.41 pg/mL, n=1010). Patients with higher baseline ET-1 concentrations were more likely male, obese and to have lower LVEF, lower eGFR, worse functional status, and elevated NT-proBNP and high-sensitivity troponin-T. Adjusting for other predictive variables including NT-proBNP, higher baseline ET-1 was independently associated with worse outcomes and steeper decline in kidney function: adjusted hazard ratio (aHR) for the primary outcome of 1.95 (1.53–2.50) for tertile 3 and 1.36 (95% CI 1.06–1.75) for tertile 2; aHR for worsening HF of 2.54 (1.82–3.53) for tertile 3 and 1.54 (1.10–2.18) for tertile 2; aHR for cardiovascular death of 1.39 (1.01–1.92) for tertile 3 and 1.13 (0.82–1.57) for tertile 2; and eGFR slope −3.19 (95% CI −3.66 to −2.72) mL/min/1.73 m2 per year in tertile 3 versus −2.06 (−2.51 to −1.62) in tertile 2 and −2.35 (−2.79 to −1.91) in tertile 1, p for difference (eGFR slope)=0.002. The benefit of dapagliflozin was consistent regardless of baseline ET-1, whether analysed according to tertiles or as a continuous variable, with p-interaction for primary outcome 0.47 and 0.10 respectively. Compared to placebo, there was a trend to reduction in ET-1 level at 12 months with dapagliflozin (difference −0.12 pg/mL, p-value=0.07). Conclusions Baseline ET-1 concentration was independently associated with clinical outcomes and with more rapid decline in kidney function. The benefit of dapagliflozin was consistent across the range of ET-1 concentrations measured. Funding Acknowledgement Type of funding sources: Foundation. Main funding source(s): The DAPA-HF trial was funded by AstraZeneca. Professor John McMurray is supported by a British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217." @default.
• W4306255564 created "2022-10-15" @default.
• W4306255564 creator A5002852509 @default.
• W4306255564 creator A5005006476 @default.
• W4306255564 creator A5007964446 @default.
• W4306255564 creator A5018432247 @default.
• W4306255564 creator A5030057930 @default.
• W4306255564 creator A5034537174 @default.
• W4306255564 creator A5036948056 @default.
• W4306255564 creator A5048450888 @default.
• W4306255564 creator A5052533254 @default.
• W4306255564 creator A5058503662 @default.
• W4306255564 creator A5064441274 @default.
• W4306255564 creator A5066275468 @default.
• W4306255564 creator A5069746241 @default.
• W4306255564 creator A5076000118 @default.
• W4306255564 creator A5076360981 @default.
• W4306255564 date "2022-10-01" @default.
• W4306255564 modified "2023-10-03" @default.
• W4306255564 title "Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF" @default.
• W4306255564 doi "https://doi.org/10.1093/eurheartj/ehac544.833" @default.
• W4306255564 hasPublicationYear "2022" @default.
• W4306255564 type Work @default.
• W4306255564 citedByCount "0" @default.
• W4306255564 crossrefType "journal-article" @default.
• W4306255564 hasAuthorship W4306255564A5002852509 @default.
• W4306255564 hasAuthorship W4306255564A5005006476 @default.
• W4306255564 hasAuthorship W4306255564A5007964446 @default.
• W4306255564 hasAuthorship W4306255564A5018432247 @default.
• W4306255564 hasAuthorship W4306255564A5030057930 @default.
• W4306255564 hasAuthorship W4306255564A5034537174 @default.
• W4306255564 hasAuthorship W4306255564A5036948056 @default.
• W4306255564 hasAuthorship W4306255564A5048450888 @default.
• W4306255564 hasAuthorship W4306255564A5052533254 @default.
• W4306255564 hasAuthorship W4306255564A5058503662 @default.
• W4306255564 hasAuthorship W4306255564A5064441274 @default.
• W4306255564 hasAuthorship W4306255564A5066275468 @default.
• W4306255564 hasAuthorship W4306255564A5069746241 @default.
• W4306255564 hasAuthorship W4306255564A5076000118 @default.
• W4306255564 hasAuthorship W4306255564A5076360981 @default.
• W4306255564 hasBestOaLocation W43062555641 @default.
• W4306255564 hasConcept C126322002 @default.
• W4306255564 hasConcept C134018914 @default.
• W4306255564 hasConcept C159641895 @default.
• W4306255564 hasConcept C164705383 @default.
• W4306255564 hasConcept C207103383 @default.
• W4306255564 hasConcept C2776370428 @default.
• W4306255564 hasConcept C2777099384 @default.
• W4306255564 hasConcept C2777180221 @default.
• W4306255564 hasConcept C2777422806 @default.
• W4306255564 hasConcept C2778198053 @default.
• W4306255564 hasConcept C2778653478 @default.
• W4306255564 hasConcept C2779311642 @default.
• W4306255564 hasConcept C2780306776 @default.
• W4306255564 hasConcept C44249647 @default.
• W4306255564 hasConcept C555293320 @default.
• W4306255564 hasConcept C71924100 @default.
• W4306255564 hasConcept C78085059 @default.
• W4306255564 hasConceptScore W4306255564C126322002 @default.
• W4306255564 hasConceptScore W4306255564C134018914 @default.
• W4306255564 hasConceptScore W4306255564C159641895 @default.
• W4306255564 hasConceptScore W4306255564C164705383 @default.
• W4306255564 hasConceptScore W4306255564C207103383 @default.
• W4306255564 hasConceptScore W4306255564C2776370428 @default.
• W4306255564 hasConceptScore W4306255564C2777099384 @default.
• W4306255564 hasConceptScore W4306255564C2777180221 @default.
• W4306255564 hasConceptScore W4306255564C2777422806 @default.
• W4306255564 hasConceptScore W4306255564C2778198053 @default.
• W4306255564 hasConceptScore W4306255564C2778653478 @default.
• W4306255564 hasConceptScore W4306255564C2779311642 @default.
• W4306255564 hasConceptScore W4306255564C2780306776 @default.
• W4306255564 hasConceptScore W4306255564C44249647 @default.
• W4306255564 hasConceptScore W4306255564C555293320 @default.
• W4306255564 hasConceptScore W4306255564C71924100 @default.
• W4306255564 hasConceptScore W4306255564C78085059 @default.
• W4306255564 hasIssue "Supplement_2" @default.
• W4306255564 hasLocation W43062555641 @default.
• W4306255564 hasOpenAccess W4306255564 @default.
• W4306255564 hasPrimaryLocation W43062555641 @default.
• W4306255564 hasRelatedWork W2061321770 @default.
• W4306255564 hasRelatedWork W2090667355 @default.
• W4306255564 hasRelatedWork W2779222010 @default.
• W4306255564 hasRelatedWork W2965474825 @default.
• W4306255564 hasRelatedWork W3148497311 @default.
• W4306255564 hasRelatedWork W3211468684 @default.
• W4306255564 hasRelatedWork W4293354639 @default.
• W4306255564 hasRelatedWork W4311668626 @default.
• W4306255564 hasRelatedWork W4319835941 @default.
• W4306255564 hasRelatedWork W2035069710 @default.
• W4306255564 hasVolume "43" @default.
• W4306255564 isParatext "false" @default.
• W4306255564 isRetracted "false" @default.
• W4306255564 workType "article" @default.